Pharmaceuticals by P/E ratio
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Edgewise Therapeutics has the lowest figure of the 33 pharmaceuticals ranked by P/E ratio, at 4.9, followed by Alnylam Pharmaceuticals (7.8) and Novo Nordisk (10.0). Figures as of 18 Nov 2026, 15:38 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 33
- Lowest
- Edgewise Therapeutics4.9
- Median
- 40.3
- Combined market value
- AED 18.72T
- Countries
- 10
- Not ranked
- 28no P/E ratio on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | P/E ↑ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Edgewise TherapeuticsEWTX · Health Care | 4.9 | AED 16.5B | AED 150.34 | 2.63% down | 88% up | ||
| 2 | Alnylam PharmaceuticalsALNY · Health Care | 7.8 | AED 75.8B | AED 565.58 | 1.60% down | 66% down | ||
| 3 | Novo NordiskNVO · Health Care | 10.0 | AED 642.8B | AED 145.86 | 2.42% down | 17% down | ||
| 4 | GrifolsGRFS · Health Care | 10.3 | AED 21.3B | AED 31.26 | 1.38% down | 1% up | ||
| 5 | Bristol-Myers SquibbBMY · Health Care | 13.3 | AED 451B | AED 220.65 | 2.07% down | 34% up | ||
| 6 | ZoetisZTS · Health Care | 14.3 | AED 125.4B | AED 308.72 | 0.69% up | 29% down | ||
| 7 | GSKGSK · Health Care | 17.1 | AED 360.3B | AED 179.74 | 0.61% down | 6% up | ||
| 8 | Ascendis PharmaASND · Health Care | 17.8 | AED 65.4B | AED 996.93 | 0.10% up | 28% up | ||
| 9 | Regeneron PharmaceuticalsREGN · Health Care | 21.2 | AED 364.4B | AED 3,522.28 | 0.14% up | 36% up | ||
| 10 | United TherapeuticsUTHR · Health Care | 21.7 | AED 89.7B | AED 2,107.28 | 1.77% down | 23% up | ||
| 11 | SanofiSNY · Health Care | 23.6 | AED 417.5B | AED 173.86 | 0.40% down | 4% down | ||
| 12 | AstraZenecaAZN · Health Care | 25.3 | AED 1.02T | AED 658.13 | 1.68% down | 2% up | ||
| 13 | Protagonist TherapeuticsPTGX · Health Care | 26.4 | AED 29.9B | AED 458.30 | 0.10% up | 46% up | ||
| 14 | NovartisNVS · Health Care | 29.9 | AED 1.09T | AED 575.39 | 1.55% down | 25% up | ||
| 15 | Vertex PharmaceuticalsVRTX · Health Care | 34.4 | AED 498.4B | AED 1,965.78 | 0.20% up | 27% up | ||
| 16 | Abbott LaboratoriesABT · Health Care | 38.9 | AED 663.9B | AED 383.31 | 0.32% down | 17% down | ||
| 17 | PfizerPFE · Health Care | 40.3 | AED 590.7B | AED 103.64 | 0.88% down | 14% up | ||
| 18 | Dr. Reddy's LaboratoriesRDY · Health Care | 41.6 | AED 45.8B | AED 55.00 | 1.25% up | 5% up | ||
| 19 | Johnson & JohnsonJNJ · Health Care | 41.8 | AED 2.44T | AED 1,012.28 | 1.10% down | 38% up | ||
| 20 | GenmabGMAB · Health Care | 44.0 | AED 116.7B | AED 189.19 | 0.86% down | 70% up | ||
| 21 | Royalty PharmaRPRX · Health Care | 44.8 | AED 144.7B | AED 251.68 | 0.22% down | 78% up | ||
| 22 | Eli LillyLLY · Health Care | 45.3 | AED 4.57T | AED 5,127.65 | 1.37% down | 35% up | ||
| 23 | AbbVieABBV · Health Care | 49.5 | AED 1.87T | AED 1,058.41 | 1.58% down | 26% up | ||
| 24 | Corcept TherapeuticsCORT · Health Care | 50.7 | AED 27.1B | AED 247.88 | 3.67% down | 8% down | ||
| 25 | BeOne MedicinesONC · Health Care | 51.9 | AED 169.8B | AED 1,486.72 | 2.04% down | 17% up | ||
| 26 | Amneal PharmaceuticalsAMRX · Health Care | 53.9 | AED 27.6B | AED 79.11 | 1.99% up | 83% up | ||
| 27 | Jazz PharmaceuticalsJAZZ · Health Care | 72.3 | AED 57.6B | AED 897.27 | 1.50% up | 37% up | ||
| 28 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | 72.3 | AED 27.6B | AED 350.64 | 0.38% up | 126% up | ||
| 29 | TG TherapeuticsTGTX · Health Care | 94.9 | AED 35.3B | AED 233.39 | 1.34% up | 107% up | ||
| 30 | Teva Pharmaceutical IndustriesTEVA · Health Care | 98.4 | AED 181.3B | AED 155.39 | 0.73% down | 74% up | ||
| 31 | Ligand PharmaceuticalsLGND · Health Care | 118 | AED 21.7B | AED 1,082.39 | 0.31% up | 43% up | ||
| 32 | Merck & CoMRK · Health Care | 142 | AED 1.27T | AED 514.75 | 2.24% down | 51% up | ||
| 33 | Takeda PharmaceuticalTAK · Health Care | 306 | AED 251.2B | AED 78.63 | 1.06% down | 54% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 3.6726 AED). 28 companies have no P/E ratio on file and are not ranked here.
Questions and answers
Which pharmaceuticals have the lowest P/E ratio?
Edgewise Therapeutics (4.9), Alnylam Pharmaceuticals (7.8) and Novo Nordisk (10.0) have the lowest P/E ratio of the 33 pharmaceuticals ranked here as of 18 Nov 2026, 15:38 UTC.
How many pharmaceuticals are in this ranking?
33 are ranked by P/E ratio. 28 more have no P/E ratio on file and are left out rather than ranked at zero.
What are these pharmaceuticals worth together?
The 33 pharmaceuticals ranked by P/E ratio have a combined market value of AED 18.72T as of 18 Nov 2026, 15:38 UTC.
What does ranking by P/E ratio measure?
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- PEG ratio: P/E adjusted for growth, and its limits
The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Pharmaceuticals by P/E ratio”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=pe-ratio
Underlying data: Yahoo Finance; SEC EDGAR.